scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
38 hedge funds and large institutions have $97.9M invested in scPharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 23 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.11% less ownership
Funds ownership: 62.69% → 58.58% (-4.1%)
14% less capital invested
Capital invested by funds: $114M → $97.9M (-$16.1M)
17% less funds holding
Funds holding: 46 → 38 (-8)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
83% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$3.15M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$1.17M |
| 3 |
Millennium Management
New York
|
+$348K |
| 4 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$223K |
| 5 |
E
Ergoteles
New York
|
+$168K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$3.22M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.37M |
| 3 |
BlackRock
New York
|
-$1.61M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.29M |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.28M |
SCPH Hedge Fund Activity: Q2 2021 in Review
38 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q2 2021, worth a combined $97.9M — down 14% from $114M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SCPH and 5 opened new positions — a net loss of 8 holders — while 23 trimmed existing stakes and 4 added.
The largest buyer was J. Goldman & Co, adding an estimated $3.15M. The largest seller was Goldman Sachs, cutting an estimated $3.22M.
- 38 institutional investors held scPharmaceuticals (SCPH) as of Q2 2021, down from 46 in Q1 2021.
- Funds reported $97.9M of scPharmaceuticals stock for Q2 2021, down 14% quarter-over-quarter.
- 5 funds opened new scPharmaceuticals positions in Q2 2021 and 13 closed out, a net change of -8 holders.
- The largest scPharmaceuticals buyer in Q2 2021 was J. Goldman & Co, an estimated $3.15M added.
- The largest scPharmaceuticals seller in Q2 2021 was Goldman Sachs, an estimated $3.22M sold.
Based on aggregated 13F filings for Q2 2021.